imiquimod has been researched along with Central Nervous System Neoplasm in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruhn, KW; Craft, N; Khan-Farooqi, H; Koya, RC; Liau, LM; Miller, JF; Prins, RM; Stripecke, R | 1 |
1 other study(ies) available for imiquimod and Central Nervous System Neoplasm
| Article | Year |
|---|---|
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Topics: Adjuvants, Immunologic; Adoptive Transfer; Aminoquinolines; Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Survival; Central Nervous System Neoplasms; Dendritic Cells; Female; Flow Cytometry; gp100 Melanoma Antigen; Humans; Imaging, Three-Dimensional; Imiquimod; Immunohistochemistry; Immunotherapy, Adoptive; Lymphocyte Activation; Melanoma, Experimental; Membrane Glycoproteins; Mice; Neoplasm Proteins; Neoplasm Transplantation; T-Lymphocytes | 2006 |